Portal de Periódicos da CAPES

Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity

2002; Elsevier BV; Volume: 38; Issue: 14 Linguagem: Inglês

10.1016/s0959-8049(02)00229-0

1879-0852

Guido Cavaletti, Claudio Zanna,

Neuroblastoma Research and Treatments

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem because it represents the dose-limiting side-effect of a significant number of antineoplastic drugs [ 1 Quasthoff S Hartung H.P Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002; 249: 9-17 Crossref PubMed Scopus (731) Google Scholar ]. The incidence of CIPN varies depending on the conditions. Severe neuropathy can occur in the range of 3–7% of treated cases with single agents, but can rise up to 38% with polichemotherapy regimens [ 2 Connelly E Markman M Kennedy A et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers unexpected incidence of neurotoxicity. Gynecol. Oncol. 1996; 62: 166-168 Crossref PubMed Scopus (100) Google Scholar , 3 De Vita Jr., V.T Hellmann S Rosemberg S.A Cancer. Principles and Practice of Oncology. 5th edn. Philadelphia, Lippincott-Raven1997 Google Scholar , 4 Rose P.G Blessing J.A Gershenson D.M McGehee R Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix a gynecologic oncology group study. J. Clin. Oncol. 1999; 17: 2676-2680 Crossref PubMed Google Scholar ].